Yuan Jingjing, Zhang Qing, Wu Shengsheng, Yan Suran, Zhao Ran, Sun Yajuan, Tian Xiaoxu, Zhou Keshu
Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, People's Republic of China.
Onco Targets Ther. 2021 Mar 2;14:1553-1564. doi: 10.2147/OTT.S283486. eCollection 2021.
Mantle cell lymphoma (MCL) is an aggressive malignancy that accounts for 5-10% of non-Hodgkin's lymphoma. MiRNA-223-3p has been demonstrated to be down-regulated in MCL and is a useful prognostic factor. However, little is known about underlying molecular mechanism of miRNA-233-3p in MCL.
The expression levels of miRNA-223-3p and CHUK mRNA in MCL cells were detected by real-time quantitative PCR (RT-qPCR). The effects of miRNA-223-3p/CHUK overexpression/knockdown on MCL cell proliferation and apoptosis were measured by CCK-8 assay and annexin V PE/7-AAD-based flow cytometry/TUNEL assay, respectively. A nude mouse subcutaneous xenograft model was used to further evaluate the potential effects in vivo. Dual-luciferase reporter assay was used to verify the inhibitory effect of miRNA-223-3p on CHUK. Furthermore, the regulatory function of miRNA-223-3p on the CHUK/NF-ƘB2 axis was assessed by RT-qPCR, western blot and immunofluorescence.
In the present study, miRNA-223-3p overexpression inhibited proliferation and accelerated apoptosis of MCL cells in vitro and in vivo. The results of Luciferase reporter assay showed that CHUK was a direct target of miRNA-223-3p in HEK293T cells. Furthermore, the results of RT-qPCR, western blot confirmed that CHUK was targeted and negatively regulated by miRNA-223-3p for repressing NF-ƘB2 pathway activation in MCL cells. Importantly, CHUK overexpression promoted proliferation and suppressed apoptosis of MCL cells, whereas CHUK knockdown reversed down-regulated miRNA-223-3p -accelerated cell proliferation in vitro.
In conclusion, miRNA-223-3p affects MCL development by regulating the CHUK/NF-ƘB2 signaling pathway, which is crucial to provide a novel therapeutic strategy.
套细胞淋巴瘤(MCL)是一种侵袭性恶性肿瘤,占非霍奇金淋巴瘤的5%-10%。已证明miRNA-223-3p在MCL中表达下调,是一个有用的预后因素。然而,关于miRNA-233-3p在MCL中的潜在分子机制知之甚少。
通过实时定量PCR(RT-qPCR)检测MCL细胞中miRNA-223-3p和CHUK mRNA的表达水平。分别通过CCK-8法和基于膜联蛋白V PE/7-AAD的流式细胞术/TUNEL法检测miRNA-223-3p/CHUK过表达/敲低对MCL细胞增殖和凋亡的影响。使用裸鼠皮下异种移植模型进一步评估体内潜在作用。采用双荧光素酶报告基因检测法验证miRNA-223-3p对CHUK的抑制作用。此外,通过RT-qPCR、蛋白质免疫印迹和免疫荧光评估miRNA-223-3p对CHUK/NF-ƘB2轴的调节功能。
在本研究中,miRNA-223-3p过表达在体外和体内均抑制MCL细胞增殖并加速其凋亡。荧光素酶报告基因检测结果表明,CHUK是HEK293T细胞中miRNA-223-3p的直接靶点。此外,RT-qPCR、蛋白质免疫印迹结果证实,miRNA-223-3p靶向并负调控CHUK,以抑制MCL细胞中NF-ƘB2通路的激活。重要的是,CHUK过表达促进MCL细胞增殖并抑制其凋亡,而CHUK敲低逆转了体外miRNA-223-3p下调加速的细胞增殖。
总之,miRNA-223-3p通过调节CHUK/NF-ƘB2信号通路影响MCL的发展,这对于提供一种新的治疗策略至关重要。